BR112017007170A2 - anticorpos anti-ox40 humanizados e suas utilizações - Google Patents
anticorpos anti-ox40 humanizados e suas utilizaçõesInfo
- Publication number
- BR112017007170A2 BR112017007170A2 BR112017007170A BR112017007170A BR112017007170A2 BR 112017007170 A2 BR112017007170 A2 BR 112017007170A2 BR 112017007170 A BR112017007170 A BR 112017007170A BR 112017007170 A BR112017007170 A BR 112017007170A BR 112017007170 A2 BR112017007170 A2 BR 112017007170A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibodies
- humanized anti
- methods
- making
- disclosure provides
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462062431P | 2014-10-10 | 2014-10-10 | |
| PCT/US2015/054490 WO2016057667A1 (en) | 2014-10-10 | 2015-10-07 | Humanized anti-ox40 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112017007170A2 true BR112017007170A2 (pt) | 2017-12-19 |
Family
ID=55130798
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112017007170A BR112017007170A2 (pt) | 2014-10-10 | 2015-10-07 | anticorpos anti-ox40 humanizados e suas utilizações |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US9738723B2 (enExample) |
| EP (1) | EP3204422B1 (enExample) |
| JP (2) | JP6794348B2 (enExample) |
| KR (1) | KR20170064550A (enExample) |
| CN (1) | CN107074953A (enExample) |
| AR (1) | AR102239A1 (enExample) |
| AU (1) | AU2015328090A1 (enExample) |
| BR (1) | BR112017007170A2 (enExample) |
| CA (1) | CA2963798A1 (enExample) |
| CL (1) | CL2017000885A1 (enExample) |
| CO (1) | CO2017004516A2 (enExample) |
| ES (1) | ES2914177T3 (enExample) |
| GB (1) | GB2536324A (enExample) |
| IL (1) | IL251537A0 (enExample) |
| MX (1) | MX2017004715A (enExample) |
| RU (1) | RU2709742C2 (enExample) |
| SG (1) | SG11201702826XA (enExample) |
| TW (1) | TW201619200A (enExample) |
| WO (1) | WO2016057667A1 (enExample) |
Families Citing this family (87)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA201591495A1 (ru) | 2013-03-18 | 2016-05-31 | Биосерокс Продактс Б.В. | Гуманизированные антитела против cd134 (ox40) и применения указанных антител |
| BR112016013963A2 (pt) * | 2013-12-17 | 2017-10-10 | Genentech Inc | terapia de combinação compreendendo agonistas de ligação de ox40 e antagonistas de ligação do eixo de pd-1 |
| JP6588461B2 (ja) | 2014-03-31 | 2019-10-09 | ジェネンテック， インコーポレイテッド | 抗血管新生剤及びｏｘ４０結合アゴニストを含む併用療法 |
| CN117843799A (zh) * | 2015-01-08 | 2024-04-09 | 生物技术公司 | 激动性tnf受体结合剂 |
| GB201506411D0 (en) | 2015-04-15 | 2015-05-27 | Bergenbio As | Humanized anti-axl antibodies |
| CN115109158A (zh) | 2015-05-07 | 2022-09-27 | 阿吉纳斯公司 | 抗ox40抗体及其使用方法 |
| US20160347848A1 (en) * | 2015-05-28 | 2016-12-01 | Medimmune Limited | Therapeutic combinations and methods for treating neoplasia |
| UY36687A (es) | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
| KR20180053674A (ko) | 2015-10-02 | 2018-05-23 | 에프. 호프만-라 로슈 아게 | 공자극 tnf 수용체에 특이적인 이중특이성 항체 |
| JP6771551B2 (ja) | 2015-10-15 | 2020-10-21 | ディンフー バイオターゲット カンパニー リミテッド | 抗ｏｘ４０抗体及びその応用 |
| IL299072A (en) | 2015-12-02 | 2023-02-01 | Memorial Sloan Kettering Cancer Center | Antibodies and methods of use thereof |
| AR108377A1 (es) | 2016-05-06 | 2018-08-15 | Medimmune Llc | Proteínas de unión biespecíficas y sus usos |
| US11214618B2 (en) | 2016-06-20 | 2022-01-04 | F-Star Therapeutics Limited | LAG-3 binding members |
| WO2017220989A1 (en) | 2016-06-20 | 2017-12-28 | Kymab Limited | Anti-pd-l1 and il-2 cytokines |
| GB201612520D0 (en) | 2016-07-19 | 2016-08-31 | F-Star Beta Ltd | Binding molecules |
| US20190330374A1 (en) * | 2016-07-20 | 2019-10-31 | Igm Biosciences, Inc. | Multimeric ox40 binding molecules and uses thereof |
| JP2019530434A (ja) | 2016-08-05 | 2019-10-24 | ジェネンテック， インコーポレイテッド | アゴニスト活性を有する多価及び多重エピトープ抗体ならびに使用方法 |
| WO2018089628A1 (en) | 2016-11-09 | 2018-05-17 | Agenus Inc. | Anti-ox40 antibodies, anti-gitr antibodies, and methods of use thereof |
| SG10201914126RA (en) | 2016-12-15 | 2020-02-27 | Abbvie Biotherapeutics Inc | Anti-ox40 antibodies and their uses |
| CA3047059A1 (en) | 2016-12-19 | 2018-06-28 | Glenmark Pharmaceuticals S.A. | Novel tnfr agonists and uses thereof |
| JP7196094B2 (ja) * | 2017-03-29 | 2022-12-26 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 共刺激ｔｎｆ受容体のための二重特異性抗原結合分子 |
| JP7408396B2 (ja) | 2017-04-20 | 2024-01-05 | アーデーセー セラピューティクス ソシエテ アノニム | 併用療法 |
| JP7402691B2 (ja) | 2017-04-20 | 2023-12-21 | アーデーセー セラピューティクス ソシエテ アノニム | 抗ｃｄ２５抗体薬物複合体による併用療法 |
| JP2021501801A (ja) * | 2017-11-01 | 2021-01-21 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | 癌の処置に用いるための免疫刺激アゴニスト抗体 |
| CN112292397B (zh) * | 2017-11-24 | 2023-01-31 | 祐和医药科技(北京)有限公司 | 抗ox40抗体及其用途 |
| CN108218990B (zh) * | 2017-12-29 | 2021-03-02 | 南京优迈生物科技有限公司 | 分离的抗体或其抗原结合片段及其在肿瘤治疗中的应用 |
| TWI864129B (zh) | 2017-12-29 | 2024-12-01 | 圓祥生技股份有限公司 | 調節免疫檢查點作為癌症治療的單特異性蛋白質、其醫藥組成物、其核酸、及其用途 |
| CN111393529B (zh) * | 2018-01-29 | 2022-02-22 | 康源博创生物科技(北京)有限公司 | 与ox40l非竞争结合的抗ox40抗体 |
| WO2019178852A1 (zh) * | 2018-03-23 | 2019-09-26 | 苏州丁孚靶点生物技术有限公司 | Ox40抗原多肽及其用途 |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| CN120943884A (zh) | 2018-03-27 | 2025-11-14 | 百时美施贵宝公司 | 使用紫外线信号实时监测滴度 |
| CN110467674B (zh) * | 2018-05-11 | 2022-05-31 | 同润澳门一人有限公司 | 抗ox40的全人抗体及其制备方法和用途 |
| EA202092460A1 (ru) * | 2018-05-23 | 2021-03-24 | Бейджин, Лтд. | Антитела к ox40 и способы применения |
| EP3796942A1 (en) | 2018-05-23 | 2021-03-31 | ADC Therapeutics SA | Molecular adjuvant |
| GB201811415D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Anti-Mesothelin Anti bodies |
| GB201811403D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | Antibody molecules |
| GB201811408D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | CD137 Binding Molecules |
| TWI861005B (zh) | 2018-07-12 | 2024-11-11 | 英商英沃克斯製藥有限公司 | 結合pd-l1及cd137的抗體分子 |
| GB201811410D0 (en) | 2018-07-12 | 2018-08-29 | F Star Beta Ltd | OX40 Binding molecules |
| IL280002B2 (en) | 2018-07-12 | 2025-05-01 | F Star Beta Ltd | Antibody molecules that bind CD137 and OX40 |
| GB201811450D0 (en) | 2018-07-12 | 2018-08-29 | F Star Delta Ltd | Mesothelin and CD137 binding molecules |
| US20210277135A1 (en) | 2018-07-13 | 2021-09-09 | Bristol-Myers Squibb Company | Ox-40 agonist, pd-1 pathway inhibitor and ctla-4 inhibitor combination for use in a method of treating a cancer or a solid tumor |
| CN111040034B (zh) * | 2018-10-12 | 2022-08-30 | 广东旋玉健康生物科技有限公司 | 一种抗人cd358的单克隆抗体及其用途 |
| TW202028222A (zh) | 2018-11-14 | 2020-08-01 | 美商Ionis製藥公司 | Foxp3表現之調節劑 |
| US12269890B2 (en) | 2018-11-26 | 2025-04-08 | Nanjing GenScript Biotech Co., Ltd. | Humanized anti-human OX40 monoclonal antibody, preparation method therefor and use thereof |
| WO2020119789A1 (en) * | 2018-12-14 | 2020-06-18 | Wuxi Biologics (Shanghai) Co., Ltd. | Fully human antibodies against ox40, method for preparing the same, and use thereof |
| EP3904383A4 (en) * | 2018-12-25 | 2022-08-17 | Hanx Biopharmaceutics, Inc | ANTI-OX40 MONOCLONAL ANTIBODY AND USE THEREOF |
| US10442866B1 (en) | 2019-01-23 | 2019-10-15 | Beijing Mabworks Biotech Co. Ltd | Antibodies binding OX40 and uses thereof |
| US20220135619A1 (en) | 2019-02-24 | 2022-05-05 | Bristol-Myers Squibb Company | Methods of isolating a protein |
| US11279932B2 (en) | 2019-02-27 | 2022-03-22 | Ionis Pharmaceuticals, Inc. | Modulators of MALAT1 expression |
| CN114423449A (zh) * | 2019-03-25 | 2022-04-29 | 俄亥俄州国家创新基金会 | 联合免疫调节及其用途 |
| US20220220430A1 (en) | 2019-05-23 | 2022-07-14 | Bristol-Myers Squibb Company | Methods of monitoring cell culture media |
| KR20220016157A (ko) | 2019-05-30 | 2022-02-08 | 브리스톨-마이어스 스큅 컴퍼니 | 세포 국재화 시그너쳐 및 조합 요법 |
| US20220363760A1 (en) | 2019-05-30 | 2022-11-17 | Bristol-Myers Squibb Company | Multi-tumor gene signature for suitability to immuno-oncology therapy |
| WO2020243568A1 (en) | 2019-05-30 | 2020-12-03 | Bristol-Myers Squibb Company | Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy |
| WO2021098777A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene, Ltd. | Methods of cancer treatment using anti-ox40 antibodies in combination with pi3 kinase delta inhibitors |
| JP2023503396A (ja) * | 2019-11-21 | 2023-01-30 | ベイジーン リミテッド | 抗ｐｄ１抗体又は抗ｐｄｌ１抗体との組合せで抗ｏｘ４０抗体を用いる癌治療の方法 |
| WO2021098750A1 (en) * | 2019-11-21 | 2021-05-27 | Beigene (Beijing) Co., Ltd. | Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists |
| KR20220103105A (ko) * | 2019-11-21 | 2022-07-21 | 베이진 엘티디 | 항-tim3 항체와 병용하여 항-ox40 항체를 사용한 암 치료 방법 |
| AU2020385499A1 (en) * | 2019-11-21 | 2022-06-02 | Beigene, Ltd. | Methods of cancer treatment using anti-OX40 antibodies in combination with anti-TIGIT antibodies |
| GB201917254D0 (en) | 2019-11-27 | 2020-01-08 | Adc Therapeutics Sa | Combination therapy |
| IL293471A (en) | 2019-12-17 | 2022-08-01 | Amgen Inc | Dual interleukin-2 / tnf receptor agonist for use in medicine |
| US20230139700A1 (en) | 2020-03-23 | 2023-05-04 | Bio-Thera Solutions, Ltd. | Development and application of immune cell activator |
| JP2023523395A (ja) * | 2020-04-17 | 2023-06-05 | ハチソン メディファルマ リミテッド | 抗ｏｘ４０抗体及びその使用 |
| EP4149974A1 (en) * | 2020-05-13 | 2023-03-22 | Institut National de la Santé et de la Recherche Médicale (INSERM) | Recombinant proteins with ox40 activating properties |
| WO2022047412A1 (en) | 2020-08-31 | 2022-03-03 | Bristol-Myers Squibb Company | Cell localization signature and immunotherapy |
| EP4225770A1 (en) | 2020-10-05 | 2023-08-16 | Bristol-Myers Squibb Company | Methods for concentrating proteins |
| CN114457022A (zh) * | 2020-10-30 | 2022-05-10 | 未来智人再生医学研究院(广州)有限公司 | 一种表达ox40激活型抗体的多能干细胞及其衍生物与应用 |
| WO2022120179A1 (en) | 2020-12-03 | 2022-06-09 | Bristol-Myers Squibb Company | Multi-tumor gene signatures and uses thereof |
| WO2022133169A1 (en) | 2020-12-18 | 2022-06-23 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| WO2022146948A1 (en) | 2020-12-28 | 2022-07-07 | Bristol-Myers Squibb Company | Subcutaneous administration of pd1/pd-l1 antibodies |
| US20220233693A1 (en) | 2020-12-28 | 2022-07-28 | Bristol-Myers Squibb Company | Antibody Compositions and Methods of Use Thereof |
| GB202102396D0 (en) | 2021-02-19 | 2021-04-07 | Adc Therapeutics Sa | Molecular adjuvant |
| US20240376224A1 (en) | 2021-04-02 | 2024-11-14 | The Regents Of The University Of California | Antibodies against cleaved cdcp1 and uses thereof |
| TW202317629A (zh) * | 2021-06-29 | 2023-05-01 | 香港商高誠生物醫藥（香港）有限公司 | 抗ｏｘ４０單株抗體及其使用方法 |
| WO2023109901A1 (en) | 2021-12-17 | 2023-06-22 | Shanghai Henlius Biotech, Inc. | Anti-ox40 antibodies and methods of use |
| KR20240116755A (ko) | 2021-12-17 | 2024-07-30 | 상하이 헨리우스 바이오테크, 인크. | 항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법 |
| US20250057931A1 (en) | 2022-02-08 | 2025-02-20 | Hookipa Biotech Gmbh | Combination therapy with arenavirus particles and immune checkpoint modulators or cytokines |
| EP4490166A1 (en) | 2022-03-09 | 2025-01-15 | Bristol-Myers Squibb Company | Transient expression of therapeutic proteins |
| JP2025509749A (ja) | 2022-03-18 | 2025-04-11 | ブリストル－マイヤーズ スクイブ カンパニー | ポリペプチドの単離方法 |
| CN114591988B (zh) * | 2022-03-30 | 2023-01-13 | 北京贝来生物科技有限公司 | 一种激活肿瘤免疫的基因修饰干细胞制备方法 |
| JP2025518785A (ja) | 2022-06-02 | 2025-06-19 | ブリストル－マイヤーズ スクイブ カンパニー | 抗体組成物及びその使用方法 |
| CN114966061B (zh) * | 2022-07-28 | 2022-10-21 | 中国食品药品检定研究院 | 一种抗ox40抗体的生物活性检测方法 |
| EP4583999A1 (en) | 2022-09-09 | 2025-07-16 | Bristol-Myers Squibb Company | Methods of separating chelator |
| WO2024196952A1 (en) | 2023-03-20 | 2024-09-26 | Bristol-Myers Squibb Company | Tumor subtype assessment for cancer therapy |
| WO2025038763A1 (en) | 2023-08-15 | 2025-02-20 | Bristol-Myers Squibb Company | Ceramic hydroxyapatite chromatography flow through method |
| US20250215087A1 (en) | 2023-12-29 | 2025-07-03 | Bristol-Myers Squibb Company | Combination therapy of kras inhibitor and treg depleting agent |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5681718A (en) | 1986-03-14 | 1997-10-28 | Celltech Limited | Methods for enhanced production of tissue plasminogen activator in cell culture using alkanoic acids or salts thereof |
| US5457035A (en) | 1993-07-23 | 1995-10-10 | Immunex Corporation | Cytokine which is a ligand for OX40 |
| US6242566B1 (en) | 1994-02-10 | 2001-06-05 | Board Of Trustees Of The Leland Stanford Junior University | Ligand (ACT-4-L) to a receptor on the surface of activated CD4+ T-cells |
| US6312700B1 (en) | 1998-02-24 | 2001-11-06 | Andrew D. Weinberg | Method for enhancing an antigen specific immune response with OX-40L |
| AU7603800A (en) * | 1999-09-24 | 2001-04-24 | Human Genome Sciences, Inc. | 32 human secreted proteins |
| GB0216648D0 (en) | 2002-07-18 | 2002-08-28 | Lonza Biologics Plc | Method of expressing recombinant protein in CHO cells |
| US20080187954A1 (en) | 2004-03-10 | 2008-08-07 | Lonza Ltd. | Method For Producing Antibodies |
| AU2005279347A1 (en) | 2004-08-30 | 2006-03-09 | Lonza Biologics Plc. | Affinity- plus ion exchange- chromatography for purifying antibodies |
| CA2606809C (en) | 2005-05-06 | 2016-01-05 | Providence Health System | Trimeric ox40-immunoglobulin fusion protein and methods of use |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| EP2056874B1 (en) * | 2006-08-21 | 2012-09-19 | F. Hoffmann-La Roche AG | Tumor therapy with an anti-vegf antibody |
| US7691980B2 (en) | 2007-01-09 | 2010-04-06 | Bio-Rad Laboratories, Inc. | Enhanced capacity and purification of antibodies by mixed mode chromatography in the presence of aqueous-soluble nonionic organic polymers |
| CA2679399A1 (en) | 2007-02-27 | 2008-09-04 | Genetech, Inc. | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| EP2242771B1 (en) * | 2007-12-14 | 2013-07-17 | Bristol-Myers Squibb Company | Binding molecules to the human ox40 receptor |
| WO2009092014A1 (en) | 2008-01-18 | 2009-07-23 | Gagnon Peter S | Enhanced purification of antibodies and antibody fragments by apatite chromatography |
| PL2250279T3 (pl) | 2008-02-08 | 2016-11-30 | Przeciwciała anty-ifnar1 o zmniejszonym powinowactwie do liganda fc | |
| PT2398498T (pt) * | 2009-02-17 | 2018-12-03 | Ucb Biopharma Sprl | Moléculas de anticorpo tendo especificidade para ox40 humano |
| DK2663579T3 (en) | 2011-01-14 | 2017-07-31 | Univ California | THERAPEUTIC ANTIBODIES AGAINST ROR-1 PROTEIN AND PROCEDURES FOR USE THEREOF |
| HRP20180858T1 (hr) * | 2011-07-11 | 2018-09-21 | Glenmark Pharmaceuticals S.A. | Protutijela koja se vežu na ox40 i njihove uporabe |
| JP6038920B2 (ja) * | 2011-08-23 | 2016-12-07 | ボード・オブ・リージエンツ，ザ・ユニバーシテイ・オブ・テキサス・システム | 抗ｏｘ４０抗体およびそれを使用する方法 |
| GB201116092D0 (en) | 2011-09-16 | 2011-11-02 | Bioceros B V | Antibodies and uses thereof |
| ES2740358T3 (es) | 2012-02-06 | 2020-02-05 | Providence Health & Services Oregon | Método de supervisión del tratamiento del cáncer con agonistas de OX40 |
| EP2819693A4 (en) * | 2012-03-02 | 2015-10-28 | Providence Health & Services Oregon | ANTICANCER BITHERAPY BASED ON OX40 / IL-2 AGONIST |
| EP2970445A4 (en) * | 2013-03-12 | 2017-02-22 | Decimmune Therapeutics Inc. | Humanized anti-n2 antibodies |
| EA201591495A1 (ru) * | 2013-03-18 | 2016-05-31 | Биосерокс Продактс Б.В. | Гуманизированные антитела против cd134 (ox40) и применения указанных антител |
-
2015
- 2015-10-01 TW TW104132442A patent/TW201619200A/zh unknown
- 2015-10-07 WO PCT/US2015/054490 patent/WO2016057667A1/en not_active Ceased
- 2015-10-07 EP EP15848683.7A patent/EP3204422B1/en active Active
- 2015-10-07 JP JP2017518907A patent/JP6794348B2/ja active Active
- 2015-10-07 SG SG11201702826XA patent/SG11201702826XA/en unknown
- 2015-10-07 KR KR1020177012413A patent/KR20170064550A/ko not_active Withdrawn
- 2015-10-07 AU AU2015328090A patent/AU2015328090A1/en not_active Abandoned
- 2015-10-07 RU RU2017115662A patent/RU2709742C2/ru active
- 2015-10-07 US US14/877,547 patent/US9738723B2/en active Active
- 2015-10-07 CA CA2963798A patent/CA2963798A1/en not_active Abandoned
- 2015-10-07 BR BR112017007170A patent/BR112017007170A2/pt not_active Application Discontinuation
- 2015-10-07 MX MX2017004715A patent/MX2017004715A/es unknown
- 2015-10-07 CN CN201580056175.7A patent/CN107074953A/zh active Pending
- 2015-10-07 ES ES15848683T patent/ES2914177T3/es active Active
- 2015-10-08 GB GB1517855.1A patent/GB2536324A/en not_active Withdrawn
- 2015-10-09 AR ARP150103284A patent/AR102239A1/es unknown
-
2017
- 2017-04-03 IL IL251537A patent/IL251537A0/en unknown
- 2017-04-10 CL CL2017000885A patent/CL2017000885A1/es unknown
- 2017-05-04 CO CONC2017/0004516A patent/CO2017004516A2/es unknown
- 2017-06-28 US US15/635,847 patent/US10150815B2/en active Active
-
2018
- 2018-12-10 US US16/215,263 patent/US20190169303A1/en not_active Abandoned
-
2020
- 2020-11-11 JP JP2020187650A patent/JP2021036887A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| EP3204422B1 (en) | 2022-03-30 |
| US9738723B2 (en) | 2017-08-22 |
| GB201517855D0 (en) | 2015-11-25 |
| WO2016057667A1 (en) | 2016-04-14 |
| RU2709742C2 (ru) | 2019-12-19 |
| CL2017000885A1 (es) | 2017-12-15 |
| CA2963798A1 (en) | 2016-04-14 |
| US20190169303A1 (en) | 2019-06-06 |
| CN107074953A (zh) | 2017-08-18 |
| KR20170064550A (ko) | 2017-06-09 |
| RU2017115662A3 (enExample) | 2019-05-20 |
| RU2017115662A (ru) | 2018-11-13 |
| TW201619200A (zh) | 2016-06-01 |
| JP2021036887A (ja) | 2021-03-11 |
| SG11201702826XA (en) | 2017-05-30 |
| AR102239A1 (es) | 2017-02-15 |
| EP3204422A1 (en) | 2017-08-16 |
| US20180072808A1 (en) | 2018-03-15 |
| CO2017004516A2 (es) | 2017-09-29 |
| GB2536324A (en) | 2016-09-14 |
| EP3204422A4 (en) | 2018-08-15 |
| MX2017004715A (es) | 2017-06-19 |
| US10150815B2 (en) | 2018-12-11 |
| AU2015328090A1 (en) | 2017-04-27 |
| US20160137740A1 (en) | 2016-05-19 |
| JP6794348B2 (ja) | 2020-12-09 |
| IL251537A0 (en) | 2017-05-29 |
| JP2017532037A (ja) | 2017-11-02 |
| ES2914177T3 (es) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
| ZA202107931B (en) | Anti-tau antibodies and methods of use | |
| PH12016501894A1 (en) | Anti-ox40 antibodies and methods of use | |
| MX2020009649A (es) | Anticuerpos monoclonales contra bcma. | |
| EA201790545A1 (ru) | Антитела и иммуноконъюгаты против her2 | |
| EA201790569A1 (ru) | Антитела и иммуноконъюгаты против cll-1 | |
| PH12017500877B1 (en) | ANTI-CD79b ANTIBODIES AND METHODS OF USE | |
| BR112018003269A2 (pt) | conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização | |
| CL2016001871A1 (es) | Anticuerpos humanos para pd-1 | |
| MX2019001471A (es) | Anticuerpos anti-siglec-7 para el tratamiento del cancer. | |
| NZ731467A (en) | Anti-tim3 antibodies and methods of use | |
| HUE053191T2 (hu) | 2-Heteroaril-3-oxo-2,3-dihidropiridazin-4-karboxamidok rák kezelésére | |
| LT3110440T (lt) | Anti-cd38 antikūnai, skirti ūminės limfoblastinės leukemijos gydymui | |
| PH12016502061A1 (en) | Novel antii-rnf43 antibodies and methods of use | |
| MX2016010433A (es) | Anticuerpos anti-jagged1 y metodos de uso. | |
| BR112017013568A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
| MX2019006330A (es) | Anticuerpos anti-tau y metodos de uso. | |
| MX2016015162A (es) | Anticuerpos anti - gpc3 e inmunoconjugados. | |
| BR112018010279A2 (pt) | novos anticorpos anti-emr2 e métodos de uso | |
| BR112018012884A2 (pt) | novos anticorpos anti-mmp16 e métodos de uso | |
| BR112018012883A2 (pt) | novos anticorpos anti-upk1b e métodos de uso | |
| MX2016016233A (es) | Anticuerpos anti-lgr5 y sus usos. | |
| BR112017020374A2 (pt) | compostos bicíclicos fundidos para o tratamento de doença | |
| BR112017010627A2 (pt) | compostos bicíclicos fundidos para o tratamento de doenças | |
| NZ744340A (en) | Anti-jagged1 antibodies and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |